With BPC-157
Complementary evidenceLv2
An exploratory rat Achilles-tendon study found improved histology versus control for the combination, but no additional benefit over either peptide alone.
Interaction evidence sourceFDA TB-500 assessment All research profiles
Blends
Tri-Heal
Prepared by the ezGLP team. Sources last checked . Profile reviewed .
Also known as TB-500 + BPC-157 + KPV
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Educational overview
Tri-Heal is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
Tri-Heal is a vendor name for a fixed-ratio compounded blend of three tissue-repair research peptides in one vial, and its composition varies by seller. The catalogue entry here lists it as TB-500 with BPC-157 and KPV; other suppliers sell a Tri-Heal that substitutes GHK-Cu for KPV, so the name alone does not identify what is in a given vial. TB-500 is a short synthetic fragment of thymosin beta-4, usually the actin-binding segment. BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice. KPV is the tripeptide lysine-proline-valine from the C-terminal end of alpha-melanocyte-stimulating hormone.
Fixed-ratio compounded blends have no combined trial evidence, and nothing has been published on these three peptides administered together. Evidence for the parts does not transfer to the mixture. The parts themselves are preclinical: a 2025 systematic review in orthopaedic sports medicine found no high-quality human evidence for BPC-157, no human clinical trial of TB-500 has been published, and KPV rests on cell-culture and mouse colitis work, most cited among it a 2008 Gastroenterology study describing uptake through the PepT1 transporter and reduced NF-kB signaling. The FDA reported in 2023 that it had identified no human exposure data for KPV by any route.
Regulators treat blends of this kind as unapproved compounded preparations. None of the three components is an approved medicine anywhere, and in 2023 the FDA placed BPC-157, thymosin beta-4 and the TB-500 fragment, KPV, and injectable GHK-Cu on its list of bulk drug substances that may present significant safety risks when compounded, which excludes them from routine compounding under section 503A. In sport, BPC-157 has been named on the WADA Prohibited List since the 2022 edition under S0, non-approved substances, and thymosin beta-4 and its derivatives fall under S2; KPV and GHK-Cu are not named, although S0 covers non-approved substances generally.
The blend is supplied as a lyophilized powder in a single vial, reconstituted before subcutaneous injection, with a total peptide mass per vial and a component split set by the seller rather than by any standard. Because vendors disagree about the third ingredient, the vial label and certificate of analysis are the only record of what a particular batch contains, and neither is independently verified. No approved label sets storage temperature or beyond-use time, and no stability data cover three peptides sharing one solution. An inventory record therefore usually names each component and its stated amount alongside lot number, reconstitution date, concentration, and storage temperature.
- Category
- Blends
- Routes represented
- Subcutaneous (SubQ)
- Storage context
- Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.
Published literature
Safety evidence
Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.
A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.
Safety evidence sourceInteraction evidence
These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
With GHK-Cu
Complementary evidenceLv1
The pair is proposed as complementary from separate evidence involving thymosin-beta-4-related cell migration and GHK-Cu-associated matrix accumulation.
Interaction evidence sourceGHK-Cu wound studyFDA TB-500 assessmentWith BPC-157
Complementary evidenceLv1
The pair is proposed as complementary from separate preclinical evidence for tissue repair and reduced inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentWith KPV
Complementary evidenceLv1
The pair is proposed as complementary through separate preclinical rationales involving tissue migration, remodeling, and inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentWith GHK-Cu
Complementary evidenceLv1
The pair is proposed as complementary from separate preclinical findings involving extracellular-matrix deposition and reduced inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentCommon questions
What is in Tri-Heal peptide blend?
It depends on the seller. The composition recorded in this catalogue is TB-500, BPC-157, and KPV, while other vendors market a Tri-Heal containing GHK-Cu in place of KPV. There is no standard formula, no regulator-reviewed specification, and no requirement that two vials sold under the name match. The certificate of analysis supplied with a given batch is the only description of what it holds.
Is Tri-Heal FDA approved?
No. None of the peptides sold under this name is approved as a medicine in any country, and no regulator has reviewed the combination. In 2023 the FDA placed BPC-157, the TB-500 fragment and thymosin beta-4, KPV, and injectable GHK-Cu among bulk drug substances that may present significant safety risks when compounded, so licensed pharmacies cannot routinely prepare them under section 503A.
Is there any research on a three-peptide healing blend?
No published clinical or animal study has tested these peptides administered together as one product. The literature treats each separately, and the FDA assessed each separately. Findings reported for BPC-157 in rodent tendon and gut models, for full-length thymosin beta-4 in wound models, and for KPV in mouse colitis were generated with single agents and say nothing about how a mixture behaves.
Is Tri-Heal banned in sport?
Its named components are. The WADA Prohibited List names BPC-157 under S0, non-approved substances, and thymosin beta-4 and its derivatives, with TB-500 given as the example, under S2 peptide hormones and growth factors, both prohibited at all times. KPV and GHK-Cu are not listed by name, although the S0 category extends to substances with no approval for human therapeutic use.
Further reading
- Vasireddi et al., HSS Journal 2025 (systematic review, orthopaedic sports medicine)
- Biological activities of thymosin beta-4 defined by active peptide sequences, FASEB Journal 2010
- Dalmasso et al., Gastroenterology 2008 (PepT1-mediated KPV uptake, mouse colitis)
- FDA, KPV compounding safety assessment
- FDA, thymosin beta-4 fragment (TB-500) compounding safety assessment
- FDA, bulk drug substances that may present significant safety risks (2023)
- WADA Prohibited List (S0 non-approved substances; S2 peptide hormones and growth factors)
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.